Xenon Pharmaceuticals
Open
$52.10
Prev. Close
$52.16
High
$52.12
Low
$52.00
Market Snapshot
$4.33B
-11.3
-3.02
358
Xenon Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. The company is headquartered in Vancouver, British Columbia and currently employs 358 full-time employees. The company went IPO on 2014-10-17. The firm is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, a novel, highly potent, selective Kv7 potassium channel opener, represents the advanced, clinically validated potassium channel modulator in late-stage clinical development for the treatment of multiple indications that include epilepsy, including focal onset seizures (FOS), and primary generalized tonic-clonic seizures (PGTCS), as well as neuropsychiatric disorders including major depressive disorder (MDD), and bipolar depression (BPD). The firm is evaluating multiple therapeutic candidates targeting Kv7, Nav1.7, and Nav1.1 across various indications.
Xenon Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. The company is headquartered in Vancouver, British Columbia and currently employs 358 full-time employees. The company went IPO on 2014-10-17. The firm is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, a novel, highly potent, selective Kv7 potassium channel opener, represents the advanced, clinically validated potassium channel modulator in late-stage clinical development for the treatment of multiple indications that include epilepsy, including focal onset seizures (FOS), and primary generalized tonic-clonic seizures (PGTCS), as well as neuropsychiatric disorders including major depressive disorder (MDD), and bipolar depression (BPD). The firm is evaluating multiple therapeutic candidates targeting Kv7, Nav1.7, and Nav1.1 across various indications.
Recently from Cashu
Xenon Pharmaceuticals Advances Epilepsy Treatment with Upcoming NDA for Azetukalner by 2026
Xenon Pharmaceuticals (Ticker: XENE) is making significant strides in the realm of epilepsy treatment following promising results from its Phase III clinical trials for azetukalner. The company announ…
Xenon Pharmaceuticals Advances Neurological Drug Development with Promising Phase III Trial Results.
Xenon Pharmaceuticals showcases promising advancements in drug development with Azetukalner, a medication aimed at treating neurological disorders, as evidenced by the strong Phase III clinical trial…
Xenon Pharmaceuticals Advances Epilepsy Treatment with Successful X-TOLE2 Trial Results
Xenon Pharmaceuticals Pioneers New Frontiers in Epilepsy Treatment with X-TOLE2 Trial Success Xenon Pharmaceuticals Inc. has achieved a significant milestone with its recent Phase 3 clinical trial, X-…
Xenon Pharmaceuticals Achieves Positive Phase 3 Trial Results for Innovative Seizure Treatment
Xenon Pharmaceuticals Advances Seizure Treatment in Positive Phase 3 Trial Results Xenon Pharmaceuticals Inc. (NASDAQ:XENE) makes significant strides in developing innovative treatments for epilepsy,…